Information  X 
Enter a valid email address

Ibstock PLC (IBST)

  Print      Mail a friend

Wednesday 08 July, 2020

Ibstock PLC

Notification of Half Year Results

RNS Number : 4248S
Ibstock PLC
08 July 2020
 

8 July 2020

Notification of Half Year Results

Ibstock plc ('Ibstock' or the 'Group'), a leading manufacturer of clay bricks and concrete products in the United Kingdom, will announce its Half Year Results for the six months ended 30 June 2020 on Thursday 6 August 2020.

Enquiries to:

Ibstock plc


Joe Hudson, CEO


Chris McLeish, CFO


Robert Coates, Investor Relations Director

07880 486329



Citigate Dewe Rogerson

020 7638 9571

Kevin Smith


Nick Hayns


 

About Ibstock Plc

Ibstock plc is a leading manufacturer of clay bricks and a diversified range of clay and concrete products, from its operations in the United Kingdom. Its principal products are clay bricks, brick components, concrete roof tiles, concrete substitutes for stone masonry, concrete fencing and pre‐stressed concrete products.

 

The Group's two divisions are:

 

Ibstock Clay: The leading manufacturer by volume of clay bricks sold in the United Kingdom. With 19 manufacturing sites Ibstock Brick has the largest brick production capacity in the United Kingdom. It operates a network of 23 active quarries located close to its manufacturing plants. Ibstock Brick has recently commissioned a new soft mud brick manufacturing plant in Leicestershire that added approximately 100 million bricks to its brick production capacity per annum. Ibstock Kevington provides masonry and pre-fabricated component building solutions, operating from 5 sites across the UK.

 

Ibstock Concrete: A leading manufacturer of concrete roofing, walling, flooring and fencing products, along with lintels and general concrete building products, with 16 manufacturing plants in the United Kingdom.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORFLFFLDRITIII

a d v e r t i s e m e n t